Dose Insider / Glossary / Bone mineral density

Bone mineral densityWhat the test measures, and what weight loss on a GLP-1 does to it

Updated November 20, 2026 · 3 min read · MedlinePlus BMD test; Jensen 2024; 2025 joint nutrition advisory

Bone mineral density, or BMD, is the amount of calcium and other minerals in an area of bone.

16.9 kgLiraglutide plus exercise, weight lost in one year
Weight lost in one yearAfter an 8-week diet, kg, by groupLiraglutide plus exercise16.9 kgLiraglutide alone13.7 kgExercise alone11.2 kgPlacebo7.0 kgWeight lost in one yearAfter an 8-week diet, kg, by groupLiraglutide plus exercise16.9 kgLiraglutide alone13.7 kgExercise alone11.2 kgPlacebo7.0 kg

With exercise added, bone density did not differ from placebo.

On this page

A BMD test uses it to find bone loss and osteoporosis and to predict the risk of fractures; the most common and accurate method is a DXA scan, which uses low-dose X-rays.1 It matters on GLP-1 medicines because, as a 2024 trial put it, a major concern with weight loss is the bone loss that comes with it.2

The scan

There are two kinds of DXA scan. A central scan, done lying on a table, passes over the lower spine and hip and is the best test for predicting fractures, especially of the hip. Smaller peripheral machines measure the wrist, fingers, leg or heel. The scan is painless, and its radiation dose is lower than that of a chest X-ray.1

Reading the result

Results come as two scores. A T-score compares bone density with that of a healthy young woman; a Z-score compares it with people of the same age, sex and race. A negative number means thinner bones than the comparison group, and the more negative, the higher the fracture risk.1

The test does not diagnose a fracture; it helps predict the risk of one in the future, together with other risk factors. Treatment decisions depend on total fracture risk, which can be estimated with a tool called FRAX.1

What a GLP-1 trial found

A trial in Copenhagen, run from 2016 to 2019, enrolled 195 adults aged 18 to 65 with obesity, a BMI of 32 to 43, and no diabetes; 64% were women. Their average age was 42.84 and their average BMI 37.00. Everyone first followed an 8-week diet of 800 kcal a day and was then assigned for 52 weeks to exercise, liraglutide 3.0 mg a day, both, or placebo. Over the whole study, weight fell by 7.03 kg on placebo, 11.19 kg with exercise, 13.74 kg on liraglutide and 16.88 kg with both.2

The main outcome was the change in bone density at the hip, the lumbar spine and the forearm, measured by DXA from before the diet to the end. At the hip and spine the results split along exercise:2

The 2025 nutrition advisory from four medical societies cites this trial: a year of a GLP-1 drug with exercise training kept bone density steady, while the drug alone lowered it.3 It was one trial, with liraglutide, and the differences were small. The same advisory recommends resistance training to help preserve lean mass during weight loss.

Who is tested

The US Preventive Services Task Force recommends the test for women 65 and older and for some younger women at higher risk. There is no full agreement on screening men. Risk factors that can call for an earlier test include a fracture after 50, a strong family history of osteoporosis and early menopause. So do long-term corticosteroids, past treatment for prostate or breast cancer, rheumatoid arthritis, diabetes, thyroid imbalance and anorexia nervosa. Low body weight, under 127 pounds or a BMI under 20, and a marked loss of height count too.1 Before a scan, calcium supplements are skipped for 24 hours, metal items such as jewelry and buckles are removed, and a possible pregnancy should be mentioned first.1

Sources

  1. MedlinePlus. Bone mineral density test. A.D.A.M. Medical Encyclopedia; review date April 1, 2025, read November 20, 2026. medlineplus.gov
  2. Jensen SBK, Sørensen V, Sandsdal RM, et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial. JAMA Netw Open 2024;7:e2416775. doi:10.1001/jamanetworkopen.2024.16775
  3. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring) 2025;33:1475-1503. doi:10.1002/oby.24336

Related analyses

Log your strength sessions next to your weight; exercise is what protected bone in the trial.

Open Dose Insider